Jusvinza treatment resolution in confirmed COVID-19 patients. Santiago de Cuba, 2021
<strong>Foundation</strong>: SARS-CoV-2 infection is the most important emerging disease of this century. In this context, the Cuban Biotechnology and Pharmaceutical Industries Group (BioCubaFarma) created therapeutic alternatives to combat COVID-19, including the use of Jusvinza, which...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | Spanish |
| Published: |
Centro Provincial de Información de Ciencias Médicas. Cienfuegos
2024-01-01
|
| Series: | Medisur |
| Subjects: | |
| Online Access: | http://medisur.sld.cu/index.php/medisur/article/view/45089 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | <strong>Foundation</strong>: SARS-CoV-2 infection is the most important emerging disease of this century. In this context, the Cuban Biotechnology and Pharmaceutical Industries Group (BioCubaFarma) created therapeutic alternatives to combat COVID-19, including the use of Jusvinza, which is part of the protocol used in the country. <br /><strong>Objective</strong>: to determine the Jusvinza therapeutic resolution in confirmed COVID-19 patients. <br /><strong>Methods</strong>: a descriptive study carried out from January to September 2021, at the Dr. Joaquín Castillo Duany Military Hospital, in Santiago de Cuba. The universe consisted of 166 confirmed COVID-19 cases, to whom Jusvinza was administered. Some clinical variables (clinical status, associated non-communicable diseases, clinical progression), epidemiological (age, sex) and pharmacological (resolving, duration in days) were analyzed. A data extraction form was used, which was taken from the medical records. <br /><strong>Results</strong>: morbidity and mortality from COVID-19 was higher in males, related to comorbidities and age over 60 years; The female sex was the one with the greatest response to treatment with Jusvinza (71.7%), which increased its percentage in the absence of associated chronic non-communicable diseases (81.4%). High-risk patients had the lowest mortality (15.8%). <br /><strong>Conclusions</strong>: resolution in confirmed COVID-19 patients treated with Jusvinza was higher in high-risk cases than in severe and critical cases. |
|---|---|
| ISSN: | 1727-897X |